We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+4.37%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.14B
AUM Growth
+$113M
Cap. Flow
+$131M
Cap. Flow %
11.52%
Top 10 Hldgs %
48.07%
Holding
60
New
9
Increased
13
Reduced
15
Closed
3

Top Buys

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$33.5M
2
ARRY
Array Biopharma Inc
ARRY
+$24.8M
3
ACIU icon
AC Immune
ACIU
+$20.3M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$16.8M
5
REPL icon
Replimune Group
REPL
+$16M

Top Sells

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$11.6M
2
ARQL
Arqule Inc
ARQL
+$9.22M
3
ANAB icon
AnaptysBio
ANAB
+$7.05M
4
ONCT
Oncternal Therapeutics, Inc. Common Stock
ONCT
+$5.91M
5
FBRX icon
Forte Biosciences
FBRX
+$4.4M

Sector Composition

Rank Sector Weight
1 Healthcare 84.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
26
Xenon Pharmaceuticals
XENE
$6.2B
$15.4M 1.35%
1,165,553
+444,723
+62% +$5.15M
MTEM
27
DELISTED
Molecular Templates, Inc.
MTEM
$15M 1.32%
185,842
+139,933
+305% +$10.7M
CTIC
28
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$15M 1.32%
6,929,690
– –
RCUS icon
29
Arcus Biosciences
RCUS
$3.55B
$14.8M 1.3%
1,058,840
+99,000
+10% +$1.26M
REPL icon
30
Replimune Group
REPL
$14.7M 1.29%
+911,852
New +$16M
VSTM icon
31
Verastem
VSTM
$536M
$14.4M 1.27%
165,583
-21,280
-11% -$2.12M
KALV
32
DELISTED
KalVista Pharmaceuticals
KALV
$13.5M 1.18%
+609,014
New +$8.23M
CALA
33
DELISTED
Calithera Biosciences, Inc
CALA
$13.4M 1.17%
+127,200
New +$12.1M
LITS
34
Lite Strategy Inc
LITS
$33.6M
$13.3M 1.17%
154,015
– –
FSTX
35
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$11.5M 1.01%
238,325
+41,837
+21% +$2.1M
SNDX icon
36
Syndax Pharmaceuticals
SNDX
$1.73B
$9.97M 0.88%
1,233,618
– –
OMED
37
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$8.57M 0.75%
4,042,989
-56,600
-1% -$136K
CDTX
38
DELISTED
Cidara Therapeutics
CDTX
$8.49M 0.75%
96,534
– –
VBIV
39
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$7.5M 0.66%
103,333
– –
ALBO
40
DELISTED
Albireo Pharma Inc
ALBO
$7.21M 0.63%
218,800
-1,200
-0.5% -$39.2K
CFRX
41
DELISTED
ContraFect Corporation
CFRX
$7.2M 0.63%
4,348
+147
+3% +$243K
PRNB
42
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$7.01M 0.62%
+240,000
New +$6.77M
MACK
43
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$5.92M 0.52%
1,411,557
– –
ARGX icon
44
argenx
ARGX
$54.6B
$5.83M 0.51%
+76,808
New +$6.81M
TSRO
45
DELISTED
TESARO, Inc.
TSRO
$5.46M 0.48%
+140,000
New +$4.94M
PHXM
46
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$5.45M 0.48%
62,500
– –
GNCA
47
DELISTED
Genocea Biosciences, Inc.
GNCA
$4.11M 0.36%
658,125
– –
ALPN
48
DELISTED
Alpine Immune Sciences Inc
ALPN
$4.07M 0.36%
643,059
– –
SURF
49
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$3.94M 0.35%
360,218
+25,885
+8% +$303K
VIRX
50
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.37M 0.3%
48,132
– –
1
2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2018 Portfolio in Review

As of Q3 2018, BVF Inc held 60 positions worth $1.14B, up 11% from $1.02B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

BVF Inc deployed $131M of net new capital in Q3 2018, opening 9 new positions and adding to 13 existing holdings. Its largest new stake was AC Immune: 2,017,500 shares worth $16.1M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 84% a quarter earlier.

On the sell side, the largest reduction was Arqule Inc, an estimated $9.22M trimmed.

  • BVF Inc's largest Q3 2018 buy was AC Immune: 2,017,500 shares worth $16.1M.
  • BVF Inc added most to Five Prime Therapeutics, Inc. in Q3 2018, an estimated $33.5M increase.
  • BVF Inc's biggest Q3 2018 reduction was Arqule Inc, cutting an estimated $9.22M.
  • BVF Inc fully exited Ironwood Pharmaceuticals in Q3 2018, selling an estimated $11.6M.
  • BVF Inc's ten largest holdings make up 48% of its $1.14B portfolio in Q3 2018.
  • BVF Inc opened 9 new positions and closed 3 in Q3 2018.
  • BVF Inc's portfolio value rose 11% quarter-over-quarter to $1.14B.

Based on BVF Inc's 13F filing for Q3 2018, filed 14 Nov 2018.